Heterogeneity and Plasticity of Breast Cancer Stem Cells

Adv Exp Med Biol. 2019:1139:83-103. doi: 10.1007/978-3-030-14366-4_5.

Abstract

In the last 20 years, the conventional view of breast cancer as a homogeneous collection of highly proliferating malignant cells was totally replaced by a model of increased complexity, which points out that breast carcinomas are tissues composed of multiple populations of transformed cells. A large diversity of host cells and structural components of the extracellular matrix constitute the mammary tumour microenvironment, which supports its growth and progression, where individual cancer cells evolve with cumulative phenotypic and genetic heterogeneity. Moreover, contributing to this heterogeneity, it has been demonstrated that breast cancers can exhibit a hierarchical organization composed of tumour cells displaying divergent lineage biomarkers and where, at the apex of this hierarchy, some neoplastic cells are able to self-renew and to aberrantly differentiate. Breast cancer stem cells (BCSCs), as they were entitled, not only drive tumourigenesis, but also mediate metastasis and contribute to therapy resistance.Recently, adding more complexity to the system, it has been demonstrated that BCSCs maintain high levels of plasticity, being able to change between mesenchymal-like and epithelial-like states in a process regulated by the tumour microenvironment. These stem cell state transitions play a fundamental role in the process of tumour metastasis, as well as in the resistance to putative therapeutic strategies to target these cells. In this chapter, it will be mainly discussed the emerging knowledge regarding the contribution of BCSCs to tumour heterogeneity, their plasticity, and the role that this plasticity can play in the establishment of distant metastasis. A major focus will also be given to potential clinical implications of these discoveries in breast cancer recurrence and to possible BCSC targeted therapeutics by the use of specific biomarkers.

Keywords: Biomarkers; Breast cancer; Breast cancer stem cells (BCSCs); ECM (extracellular matrix); EMT (epithelial-to-mesenchymal transition); MET (mesenchymal-to-epithelial transition); Metabolism; Metastasis; Plasticity; Stem cells; Stemness; Therapy resistance; Tumour heterogeneity; Tumour microenvironment.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Breast Neoplasms / pathology*
  • Epithelial-Mesenchymal Transition
  • Female
  • Humans
  • Neoplasm Recurrence, Local
  • Neoplastic Stem Cells / cytology*
  • Tumor Microenvironment*

Substances

  • Biomarkers, Tumor